Analysts expect that C.R. Bard, Inc. (NYSE:BCR) will announce earnings of $2.84 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for C.R. Bard’s earnings. The lowest EPS estimate is $2.80 and the highest is $2.92. C.R. Bard reported earnings per share of $2.56 during the same quarter last year, which indicates a positive year over year growth rate of 10.9%. The company is expected to report its next quarterly earnings results on Tuesday, July 25th.
According to Zacks, analysts expect that C.R. Bard will report full-year earnings of $11.79 per share for the current year, with EPS estimates ranging from $11.63 to $11.91. For the next fiscal year, analysts anticipate that the company will post earnings of $12.93 per share, with EPS estimates ranging from $12.49 to $13.15. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for C.R. Bard.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. The firm had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. C.R. Bard’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.34 EPS.
Several analysts have recently weighed in on the company. Cowen and Company lifted their price objective on C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a report on Monday, April 24th. BidaskClub raised C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a report on Tuesday, June 6th. Jefferies Group LLC boosted their price target on C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a research note on Monday, April 24th. Finally, Wells Fargo & Company lowered C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. Ten investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $265.77.
TRADEMARK VIOLATION NOTICE: “C.R. Bard, Inc. (NYSE:BCR) Expected to Post Earnings of $2.84 Per Share” was first published by WKRB News and is owned by of WKRB News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.wkrb13.com/markets/2286523/c-r-bard-inc-nysebcr-expected-to-post-earnings-of-2-84-per-share.html.
In other news, VP Frank Lupisella, Jr. sold 3,622 shares of the business’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the completion of the sale, the vice president now owns 10,139 shares in the company, valued at $3,082,256. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in BCR. Parallel Advisors LLC increased its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares in the last quarter. Cribstone Capital Management LLC bought a new stake in C.R. Bard during the first quarter worth approximately $130,000. Contravisory Investment Management Inc. increased its stake in C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 426 shares in the last quarter. Whittier Trust Co. increased its stake in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares in the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in C.R. Bard during the first quarter worth approximately $148,000. Institutional investors and hedge funds own 88.04% of the company’s stock.
C.R. Bard (BCR) traded down 0.12% during trading on Monday, reaching $318.04. The company’s stock had a trading volume of 395,875 shares. C.R. Bard has a 52-week low of $203.63 and a 52-week high of $318.89. The firm has a market capitalization of $23.03 billion, a price-to-earnings ratio of 40.48 and a beta of 0.59. The stock’s 50-day moving average is $311.80 and its 200 day moving average is $264.06.
The company also recently announced a quarterly dividend, which will be paid on Friday, August 4th. Stockholders of record on Monday, July 24th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s payout ratio is currently 13.21%.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286523/c-r-bard-inc-nysebcr-expected-to-post-earnings-of-2-84-per-share.html
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.